© 2022 Regional Cancer Care Associates. All rights reserved.
An Open-Label, Multi-Centre Phase I/Iia Study Evaluating The Safety And Clinical Activity Of Neoantigen Reactive T Cells In Patients With Advanced Non-Small Cell Lung Cancer Read more
A Phase 1/2, Open-Label, Dose-Escalation, Safety And Tolerability Study Of NC318 In Subjects With Advanced Or Metastatic Solid Tumors Read more
Phase 1 Open-Label Study With A Novel Triple Mechanism Of Action IP In Combination With Pembrolizumab For Advanced Malignancies. Read more
A Phase 1/2, Open-Label, Dose-Escalation, Safety And Tolerability Study Of NC410 In Subjects With Advanced Or Metastatic Solid Tumors Read more
A Phase 1/2, Open-Label Study Investigating The Safety, Tolerability And Efficacy Of ASP7517 As A Single Agent And In Combination With Pembrolizumab In Patients With Advanced Solid Tumors Known To Express WT1 Antigen Read more
A Phase 1, Open-Label, Multi-Center, Dose-Finding, Pharmacokinetic, Safety And Tolerability Study Of Pf-07265807 In Participants With Selected Advanced Or Metastatic Solid Tumor Malignancies Read more
(CD47 And PD-L1) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS FQ Completed On: 2/4/2021 Read more
A Two-Part, Phase 1a/B, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety And Efficacy Of Pf-07284890 (Arry-461) In Participants With Braf V600-Mutant Solid Tumors With And Without Brain Involvement Read more
Phase II Trial Of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy Of Checkpoint Therapy Resistant Solid Tumors Read more
